Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

PIKES Analysis Reveals Response to Degraders and Key Regulatory Mechanisms of the CRL4 Network.

Reichermeier KM, Straube R, Reitsma JM, Sweredoski MJ, Rose CM, Moradian A, den Besten W, Hinkle T, Verschueren E, Petzold G, Thomä NH, Wertz IE, Deshaies RJ, Kirkpatrick DS.

Mol Cell. 2020 Jan 15. pii: S1097-2765(19)30926-8. doi: 10.1016/j.molcel.2019.12.013. [Epub ahead of print]

PMID:
31973889
2.

Metabolic and Non-Metabolic Peripheral Neuropathy: Is there a Place for Therapeutic Apheresis?

Straube R, Müller G, Voit-Bak K, Tselmin S, Julius U, Schatz U, Rietzsch H, Reichmann H, Chrousos GP, Schürmann A, Jarc L, Ziemssen T, Siepmann T, Bornstein SR.

Horm Metab Res. 2019 Dec;51(12):779-784. doi: 10.1055/a-1039-1471. Epub 2019 Dec 11.

PMID:
31826273
3.

Extracorporeal apheresis therapy for Alzheimer disease-targeting lipids, stress, and inflammation.

Bornstein SR, Voit-Bak K, Rosenthal P, Tselmin S, Julius U, Schatz U, Boehm BO, Thuret S, Kempermann G, Reichmann H, Chrousos GP, Licinio J, Wong ML, Schally AV, Straube R.

Mol Psychiatry. 2020 Feb;25(2):275-282. doi: 10.1038/s41380-019-0542-x. Epub 2019 Oct 8. Review.

PMID:
31595035
4.

Correction: Lipid Profiles in Lyme Borreliosis: A Potential Role for Apheresis?

Straube R, Voit-Bak K, Gor A, Steinmeier T, Chrousos GP, Boehm BO, Birkenfeld AL, Barbir M, Balanzew W, Bornstein SR.

Horm Metab Res. 2019 Aug;51(8):554. doi: 10.1055/a-0976-7010. Epub 2019 Aug 13. No abstract available.

PMID:
31408899
5.

Lipid Profiles in Lyme Borreliosis: A Potential Role for Apheresis?

Straube R, Voit-Bak K, Gor A, Steinmeier T, Chrousos GP, Boehm BO, Birkenfeld AL, Barbir M, Balanzew W, Bornstein SR.

Horm Metab Res. 2019 May;51(5):326-329. doi: 10.1055/a-0885-7169. Epub 2019 May 9. Erratum in: Horm Metab Res. 2019 Aug;51(8):554.

PMID:
31071737
6.

Thermal stability and epitope integrity of a lyophilized ricin toxin subunit vaccine.

Westfall J, Yates JL, Van Slyke G, Ehrbar D, Measey T, Straube R, Donini O, Mantis NJ.

Vaccine. 2018 Sep 25;36(40):5967-5976. doi: 10.1016/j.vaccine.2018.08.059. Epub 2018 Aug 29.

7.

Cand1-Mediated Adaptive Exchange Mechanism Enables Variation in F-Box Protein Expression.

Liu X, Reitsma JM, Mamrosh JL, Zhang Y, Straube R, Deshaies RJ.

Mol Cell. 2018 Mar 1;69(5):773-786.e6. doi: 10.1016/j.molcel.2018.01.038.

8.

Trade-off and flexibility in the dynamic regulation of the cullin-RING ubiquitin ligase repertoire.

Straube R, Shah M, Flockerzi D, Wolf DA.

PLoS Comput Biol. 2017 Nov 17;13(11):e1005869. doi: 10.1371/journal.pcbi.1005869. eCollection 2017 Nov.

9.

Analysis of network motifs in cellular regulation: Structural similarities, input-output relations and signal integration.

Straube R.

Biosystems. 2017 Dec;162:215-232. doi: 10.1016/j.biosystems.2017.10.012. Epub 2017 Oct 28. Review.

PMID:
29107640
10.

Operating regimes of covalent modification cycles at high enzyme concentrations.

Straube R.

J Theor Biol. 2017 Oct 27;431:39-48. doi: 10.1016/j.jtbi.2017.08.006. Epub 2017 Aug 4.

PMID:
28782551
11.

Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients.

Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Scott Z, Elder J, Sonis ST, Straube R, Donini O.

Biotechnol Rep (Amst). 2017 May 17;15:24-26. doi: 10.1016/j.btre.2017.05.002. eCollection 2017 Sep.

12.

Bistability and Nonmonotonic Induction of the lac Operon in the Natural Lactose Uptake System.

Zander D, Samaga D, Straube R, Bettenbrock K.

Biophys J. 2017 May 9;112(9):1984-1996. doi: 10.1016/j.bpj.2017.03.038.

13.

Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study.

Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Elder J, Sonis ST, Straube R, Donini O.

J Biotechnol. 2016 Dec 10;239:115-125. doi: 10.1016/j.jbiotec.2016.10.010. Epub 2016 Oct 13.

14.

A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy.

North JR, Takenaka S, Rozek A, Kielczewska A, Opal S, Morici LA, Finlay BB, Schaber CJ, Straube R, Donini O.

J Biotechnol. 2016 May 20;226:24-34. doi: 10.1016/j.jbiotec.2016.03.032. Epub 2016 Mar 23.

15.

Analysis of substrate competition in regulatory network motifs: Stimulus-response curves, thresholds and ultrasensitivity.

Straube R.

J Theor Biol. 2015 Sep 7;380:74-82. doi: 10.1016/j.jtbi.2015.05.018. Epub 2015 May 21.

PMID:
26002995
16.

Reciprocal regulation as a source of ultrasensitivity in two-component systems with a bifunctional sensor kinase.

Straube R.

PLoS Comput Biol. 2014 May 8;10(5):e1003614. doi: 10.1371/journal.pcbi.1003614. eCollection 2014 May.

17.

Sensitivity and robustness in covalent modification cycles with a bifunctional converter enzyme.

Straube R.

Biophys J. 2013 Oct 15;105(8):1925-33. doi: 10.1016/j.bpj.2013.09.010.

18.

Reciprocal enzyme regulation as a source of bistability in covalent modification cycles.

Straube R, Conradi C.

J Theor Biol. 2013 Aug 7;330:56-74. doi: 10.1016/j.jtbi.2013.04.002. Epub 2013 Apr 11. Erratum in: J Theor Biol. 2013 Sep 21;333:210.

PMID:
23583955
19.

An extended model for the repression of photosynthesis genes by the AppA/PpsR system in Rhodobacter sphaeroides.

Pandey R, Flockerzi D, Hauser MJ, Straube R.

FEBS J. 2012 Sep;279(18):3449-61. doi: 10.1111/j.1742-4658.2012.08520.x. Epub 2012 Mar 16.

20.

Comment on "load-induced modulation of signal transduction networks": reconciling ultrasensitivity with bifunctionality?

Straube R.

Sci Signal. 2012 Jan 3;5(205):lc1; author reply lc2. doi: 10.1126/scisignal.2002699.

PMID:
22215730
21.

Modeling the light- and redox-dependent interaction of PpsR/AppA in Rhodobacter sphaeroides.

Pandey R, Flockerzi D, Hauser MJ, Straube R.

Biophys J. 2011 May 18;100(10):2347-55. doi: 10.1016/j.bpj.2011.04.017.

22.

Brownian diffusion of ion channels in different membrane patch geometries.

Wei F, Yang D, Straube R, Shuai J.

Phys Rev E Stat Nonlin Soft Matter Phys. 2011 Feb;83(2 Pt 1):021919. Epub 2011 Feb 28.

PMID:
21405875
23.

Diffusive coupling can discriminate between similar reaction mechanisms in an allosteric enzyme system.

Straube R, Nicola EM.

BMC Syst Biol. 2010 Nov 30;4:165. doi: 10.1186/1752-0509-4-165.

24.

Inward rotating spiral waves in glycolysis.

Straube R, Vermeer S, Nicola EM, Mair T.

Biophys J. 2010 Jul 7;99(1):L4-6. doi: 10.1016/j.bpj.2010.04.018.

25.

[Rheopheresis for recurrent sudden hearing loss : therapeutic options for patients refractory to infusion therapy].

Uygun-Kiehne S, Straube R, Heibges A, Klingel R, Davids H.

HNO. 2010 May;58(5):445-51. doi: 10.1007/s00106-009-2004-2. German.

PMID:
20182682
26.

Investigating the effects of molecular crowding on Ca2+ diffusion using a particle-based simulation model.

Straube R, Ridgway D.

Chaos. 2009 Sep;19(3):037110. doi: 10.1063/1.3207820.

PMID:
19792035
27.

Spatial desynchronization of glycolytic waves as revealed by Karhunen-Loeve analysis.

Bagyan S, Mair T, Suchorski Y, Hauser MJ, Straube R.

J Phys Chem B. 2008 Nov 13;112(45):14334-41. doi: 10.1021/jp805087m. Epub 2008 Oct 23.

PMID:
18942874
28.

Modeling the electron transport chain of purple non-sulfur bacteria.

Klamt S, Grammel H, Straube R, Ghosh R, Gilles ED.

Mol Syst Biol. 2008;4:156. doi: 10.1038/msb4100191. Epub 2008 Jan 15.

29.

Reversible clustering under the influence of a periodically modulated binding rate.

Straube R, Falcke M.

Phys Rev E Stat Nonlin Soft Matter Phys. 2007 Jul;76(1 Pt 1):010402. Epub 2007 Jul 26.

PMID:
17677400
30.

Reduction of chemical reaction networks using quasi-integrals.

Straube R, Flockerzi D, Müller SC, Hauser MJ.

J Phys Chem A. 2005 Jan 27;109(3):441-50.

PMID:
16833364
31.

Origin of bursting oscillations in an enzyme model reaction system.

Straube R, Flockerzi D, Müller SC, Hauser MJ.

Phys Rev E Stat Nonlin Soft Matter Phys. 2005 Dec;72(6 Pt 2):066205. Epub 2005 Dec 6. Erratum in: Phys Rev E Stat Nonlin Soft Matter Phys. 2006 Jul-Dec;74(1 Pt 2):019901.

PMID:
16486038
32.

Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial.

Taylor RW, Zimmerman JL, Dellinger RP, Straube RC, Criner GJ, Davis K Jr, Kelly KM, Smith TC, Small RJ; Inhaled Nitric Oxide in ARDS Study Group.

JAMA. 2004 Apr 7;291(13):1603-9.

PMID:
15069048
33.

Differential indication of lipoprotein apheresis during pregnancy.

Klingel R, Göhlen B, Schwarting A, Himmelsbach F, Straube R.

Ther Apher Dial. 2003 Jun;7(3):359-64. Review.

PMID:
12924613
34.

Membrane differential filtration is safe and effective for the long-term treatment of Refsum syndrome--an update of treatment modalities and pathophysiological cognition.

Straube R, Gäckler D, Thiele A, Muselmann L, Kingreen H, Klingel R.

Transfus Apher Sci. 2003 Aug;29(1):85-91.

PMID:
12877898
35.

Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide.

Lipkin PH, Davidson D, Spivak L, Straube R, Rhines J, Chang CT.

J Pediatr. 2002 Mar;140(3):306-10.

PMID:
11953727
36.

Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome.

Zimmerman JL, Dellinger RP, Straube RC, Levin JL.

Crit Care Med. 2000 Sep;28(9):3149-54.

PMID:
11008973
37.

Safety of withdrawing inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn.

Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R, Rhines J, Chang CT.

Pediatrics. 1999 Aug;104(2 Pt 1):231-6.

PMID:
10429000
39.

Placebo and inhaled nitric oxide mortality the same in ARDS clinical trial.

Dellinger RP, Zimmerman JL, Taylor RW, Straube RC.

Crit Care Med. 1998 Mar;26(3):619. No abstract available.

PMID:
9504596
40.
41.

Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group.

Dellinger RP, Zimmerman JL, Taylor RW, Straube RC, Hauser DL, Criner GJ, Davis K Jr, Hyers TM, Papadakos P.

Crit Care Med. 1998 Jan;26(1):15-23.

PMID:
9428538
42.

Influence of alterations in foregoing life-sustaining treatment practices on a clinical sepsis trial. The HA-1A Sepsis Study Group.

Sprung CL, Eidelman LA, Pizov R, Fisher CJ Jr, Ziegler EJ, Sadoff JC, Straube RC, McCloskey RV.

Crit Care Med. 1997 Mar;25(3):383-7. Erratum in: Crit Care Med 1997 Jun;25(6):1092.

PMID:
9118650
43.

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR.

Ann Intern Med. 1994 Jul 1;121(1):1-5.

PMID:
8198341
44.

HA-1A in septic patients with ARDS: results from the pivotal trial.

Bigatello LM, Greene RE, Sprung CL, Panacek EA, Straube RC, Zimmerman JL, Maunder RJ, Lanken PN, Pile-Spellmann E, Stanek KS, et al.

Intensive Care Med. 1994 May;20(5):328-34.

PMID:
7930026
45.

Single-dose pharmacokinetics and safety of HA-1A, a human IgM anti-lipid-A monoclonal antibody, in pediatric patients with sepsis syndrome.

Romano MJ, Kearns GL, Kaplan SL, Jacobs RF, Killian A, Bradley JS, Moss MM, Van Dyke R, Rodriguez W, Straube RC.

J Pediatr. 1993 Jun;122(6):974-81.

PMID:
8501580
46.

HA-1A. A human monoclonal antibody for the treatment of gram-negative sepsis.

Smith CR, Straube RC, Ziegler EJ.

Infect Dis Clin North Am. 1992 Mar;6(1):253-66. Review.

PMID:
1578120
47.

Human monoclonal antibodies in sepsis.

Smith C, Straube R, Wortel C.

Neth J Med. 1991 Oct;39(3-4):177-9. No abstract available.

PMID:
1824049
48.

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NN, et al.

N Engl J Med. 1991 Feb 14;324(7):429-36.

49.

The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker.

Spector SA, Kennedy C, McCutchan JA, Bozzette SA, Straube RG, Connor JD, Richman DD.

J Infect Dis. 1989 May;159(5):822-8.

PMID:
2496173
50.

Treatment of bacterial meningitis with once daily ceftriaxone therapy.

Dankner WM, Connor JD, Sawyer M, Straube R, Spector SA.

J Antimicrob Chemother. 1988 May;21(5):637-45.

PMID:
3391863

Supplemental Content

Loading ...
Support Center